Irritable Bowel Syndrome - Pipeline Review, H1 2015

Published: Jun, 2015 | Pages: 123 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Irritable Bowel Syndrome - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Irritable Bowel Syndrome - Pipeline Review, H1 2015', provides an overview of the Irritable Bowel Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Irritable Bowel Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Irritable Bowel Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Irritable Bowel Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Irritable Bowel Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Irritable Bowel Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Irritable Bowel Syndrome Overview 10
Therapeutics Development 11
Pipeline Products for Irritable Bowel Syndrome - Overview 11
Pipeline Products for Irritable Bowel Syndrome - Comparative Analysis 12
Irritable Bowel Syndrome - Therapeutics under Development by Companies 13
Irritable Bowel Syndrome - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Irritable Bowel Syndrome - Products under Development by Companies 19
Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 21
A. Menarini Industrie Farmaceutiche Riunite Srl 21
Actavis Plc 22
Alba Therapeutics Corporation 23
Alfa Wassermann S.p.A 24
Ardelyx, Inc. 25
Astellas Pharma Inc. 26
Dong-A Socio Group 27
GIcare Pharma Inc 28
Hanmi Pharmaceuticals, Co. Ltd. 29
ImmusanT, Inc. 30
Ironwood Pharmaceuticals, Inc. 31
Juno Therapeutics Inc. 32
Ono Pharmaceutical Co., Ltd. 33
Protagonist Therapeutics Inc. 34
RaQualia Pharma Inc. 35
SK Biopharmaceuticals Co., Ltd. 36
SK Chemicals Co., Ltd. 37
Sumitomo Dainippon Pharma Co., Ltd. 38
Synergy Pharmaceuticals, Inc. 39
Synthetic Biologics, Inc. 40
Takeda Pharmaceutical Company Limited 41
Yuhan Corporation 42
Irritable Bowel Syndrome - Therapeutics Assessment 43
Assessment by Monotherapy Products 43
Assessment by Combination Products 44
Assessment by Target 45
Assessment by Mechanism of Action 47
Assessment by Route of Administration 49
Assessment by Molecule Type 51
Drug Profiles 53
(Bacillus subtilis + mosapride + Streptococcus faecium) - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
ASP-1017 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ASP-7147 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Blautix - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DA-6886 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
DSP-6952 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
eluxadoline - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
GIC-1001 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ibodutant - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
larazotide acetate - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
linaclotide - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
Monoclonal Antibody to Antagonize M3 for Irritable Bowel Syndrome - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Nexvax-2 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
ONO-2952 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
plecanatide - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
relenopride hydrochloride - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
rifaximin - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RQ-00202730 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
RQ-00310941 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SKI-3246 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Small Molecules to Inhibit SMURF2 for Fibrosis, Oncology and IBD - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
SYN-010 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Synthetic Peptides for Gastrointestinal Disorders - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Synthetic Peptides for Irritable Bowel Syndrome and Inflammatory Bowel Disease - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
TAK-480 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
tenapanor hydrochloride - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
YH-12852 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Irritable Bowel Syndrome - Recent Pipeline Updates 89
Irritable Bowel Syndrome - Dormant Projects 109
Irritable Bowel Syndrome - Discontinued Products 113
Irritable Bowel Syndrome - Product Development Milestones 115
Featured News & Press Releases 115
May 27, 2015: Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea in Adults 115
May 20, 2015: 4D pharma Provides Research Update on Clinical Development Of Blautix 115
May 19, 2015: Ardelyx Presents Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients at Digestive Disease Week 2015 116
May 18, 2015: Synthetic Biologics' Novel SYN-010 Preclinical Data Featured in Digestive Disease Week Poster 117
Feb 17, 2015: Synthetic Biologics Announces Poster Presentation of C-IBS Candidate Therapy Data at Digestive Disease Week 2015 118
Jan 05, 2015: 4D pharma Provides Research Update 119
Dec 18, 2014: Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation 119
Nov 20, 2014: Ironwood Earns $15 Million Milestone from Astellas upon Initiation of Enrollment in Linaclotide Phase III IBS-C Clinical Trial in Japan 119
Nov 04, 2014: Ironwood Pharmaceuticals Initiates Phase III Trial of 72 mcg Linaclotide in Adult Patients with Chronic Idiopathic Constipation 120
Oct 21, 2014: Synergy Pharmaceuticals Presents Positive Phase 2b Study Results for Plecanatide in Patients with Irritable Bowel Syndrome with Constipation 120
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 122
Disclaimer 123

List of Tables

Number of Products under Development for Irritable Bowel Syndrome, H1 2015 11
Number of Products under Development for Irritable Bowel Syndrome - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Development by Companies, H1 2015 (Contd..1) 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 21
Irritable Bowel Syndrome - Pipeline by Actavis Plc, H1 2015 22
Irritable Bowel Syndrome - Pipeline by Alba Therapeutics Corporation, H1 2015 23
Irritable Bowel Syndrome - Pipeline by Alfa Wassermann S.p.A, H1 2015 24
Irritable Bowel Syndrome - Pipeline by Ardelyx, Inc., H1 2015 25
Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc., H1 2015 26
Irritable Bowel Syndrome - Pipeline by Dong-A Socio Group, H1 2015 27
Irritable Bowel Syndrome - Pipeline by GIcare Pharma Inc, H1 2015 28
Irritable Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 29
Irritable Bowel Syndrome - Pipeline by ImmusanT, Inc., H1 2015 30
Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 31
Irritable Bowel Syndrome - Pipeline by Juno Therapeutics Inc., H1 2015 32
Irritable Bowel Syndrome - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 33
Irritable Bowel Syndrome - Pipeline by Protagonist Therapeutics Inc., H1 2015 34
Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc., H1 2015 35
Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 36
Irritable Bowel Syndrome - Pipeline by SK Chemicals Co., Ltd., H1 2015 37
Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 38
Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals, Inc., H1 2015 39
Irritable Bowel Syndrome - Pipeline by Synthetic Biologics, Inc., H1 2015 40
Irritable Bowel Syndrome - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 41
Irritable Bowel Syndrome - Pipeline by Yuhan Corporation, H1 2015 42
Assessment by Monotherapy Products, H1 2015 43
Assessment by Combination Products, H1 2015 44
Number of Products by Stage and Target, H1 2015 46
Number of Products by Stage and Mechanism of Action, H1 2015 48
Number of Products by Stage and Route of Administration, H1 2015 50
Number of Products by Stage and Molecule Type, H1 2015 52
Irritable Bowel Syndrome Therapeutics - Recent Pipeline Updates, H1 2015 89
Irritable Bowel Syndrome - Dormant Projects, H1 2015 109
Irritable Bowel Syndrome - Dormant Projects (Contd..1), H1 2015 110
Irritable Bowel Syndrome - Dormant Projects (Contd..2), H1 2015 111
Irritable Bowel Syndrome - Dormant Projects (Contd..3), H1 2015 112
Irritable Bowel Syndrome - Discontinued Products, H1 2015 113
Irritable Bowel Syndrome - Discontinued Products (Contd..1), H1 2015 114